We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Thomas Aller

Thomas Aller OD, FBCLA

Private practice; Myopia Warrior, Collaborator, BHVI; Editor, myopiamanagement.org; Scientific and Clinical Advisor, TreeHouse Eyes and Reopia, LLC

Thomas Aller, OD, FBCLA, graduated from UC Berkeley School of Optometry and for 28 years he has been researching the use of multifocal contacts for the control of myopia. After receiving the world’s earliest patent for a method of myopia progression control, he spent many years collaborating with BHVI on their anti-myopia program.

Dr. Aller is currently conducting clinical trials in both myopia control and hyperopic reduction with multifocal contact lenses. He has served as a Visiting Scholar at UC Berkeley and an Adjunct Professor at the University of Houston, a member of the International Myopia Institute and was a participant of Essilor’s myopia taskforce. He also serves as a scientific and clinical advisor to many companies engaged in myopia control contacts, spectacles, pharmaceuticals and related instruments. In 2015 he launched Myappia, a myopia progression control progression app. Dr. Aller is the editor of managemyopia.org, a myopia management website for eye care practitioners. 

Dr. Aller received the Award of Excellence from the Global Specialty Lens Symposium, and along with his co-authors, he also received the 2019 Garland Clay Award from the American Academy of Optometry for their paper on their randomized clinical trial of bifocal contact lenses for the control of myopia.

Disclosures

 

Dr. Aller reports the following 2019-2020 Financial Disclosures:

Commercial Interest

What was received?

For What Role?

Essilor AMERA Pte Ltd

Fee for Service, Travel

Advisor

Essilor of America

Fee for Service, Travel

Advisor

BHVI

Honoraria

Author

Pentavision

Travel Grant

Award

Pentavision

Honoraria

Speaker

Pentavision

Fee for Service

Author

WebMD

Honoraria

Speaker

Haag-Streit

Equipment/Royalties

Advisor

Visioneering

Travel grant

Speaker

Visioneering

Clinical Trial Expenses

Principal Investigator

Visioneering

Honoraria

Editor

Visioneering

Honoraria

Consultant

Specialeyes

Clinical Trial Expenses

Principal Investigator

Treehouse Eyes

Equity

Advisor

TreeHouse Eyes

Honorarium

Speaker

Reopia, LLC

Equity

Advisor